세계의 병리학 분야 AI 시장 : 제공별, 신경망별, 기능별, 이용 사례별, 최종사용자별, 지역별 - 예측(-2030년)

The global AI in pathology market is expected to reach USD 347.39 million by 2030 from USD 107.43 million in 2025 at a high CAGR of 26.5% during the forecast period. According to the Personalized Medicine Coalition Report 2022, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases. Among the newly approved treatments are seven cancer drugs and three targeting other diseases and conditions. About 47% of these approved personalized therapies were indicated for treating cancer.

By use case, the drug discovery segment accounted for the largest share in 2024.

In 2024, the drug discovery segment accounted for the largest share of the AI in pathology market. Booming pharmaceutical & biotechnology R&D expenditure, the growing high-throughput screening & imaging, the increasing use of AI algorithms in pathology image analysis for the identification & classification of diseases, and the capability of AI to speed up the development of new therapeutics are expected to boost the market.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the AI in pathology market, by end user.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest market share due to advancements in drug discovery & development and the increasing use of AI in pathology for drug toxicology testing. Biotechnology companies use AI-based digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

North America held the largest market share in 2024.

In 2024, North America accounted for the largest market share in the AI in pathology market due to strong investment in research & development and advanced healthcare infrastructure, which enables the use of high-tech machinery. The large patient pool and data availability help create a large database, which can be used to train the AI for higher accuracy and efficiency.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Key Players

The key players in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel).

Research Coverage

The report estimates the market size and future growth potential of various market segments based on offering, neural network, use case, end user, function, and region. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (development of CNNs and advanced AI models, Integration of AI into multiplex imaging, increasing cases of misdiagnoses in patients, benefits of AI-augmented telepathology, advancements in deep learning & image processing) restraints (high cost of digital pathology systems, limited AI expertise and varied regulatory guidelines for medical software, interoperability issues with legacy systems), opportunities (increasing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease progression) challenges (insufficient data for AI algorithms, data privacy, and ethical concerns, challenges associated with interpretability of AI models) influencing the growth of the AI in pathology market
• Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market
• Market Development: Comprehensive information on the lucrative emerging markets by offering, neural network, function, use case, end user, and region
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 KEY STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Revenue share analysis illustration
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET
• 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of CNNs and advanced AI models
    • 5.2.1.2 Integration of AI into multiplex imaging
    • 5.2.1.3 Increasing cases of misdiagnoses in patients
    • 5.2.1.4 Benefits of AI-augmented telepathology
    • 5.2.1.5 Advancements in deep learning & image processing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
    • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
    • 5.2.2.3 Inadequate interoperability issues with legacy systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicines
    • 5.2.3.2 Integration of multi-omics data
    • 5.2.3.3 Predictive analytics for disease progression
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Insufficient data for AI algorithms
    • 5.2.4.2 Data privacy and ethical concerns
    • 5.2.4.3 Challenges associated with interpretability of AI models
• 5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Machine learning (ML) and artificial intelligence (AI)
    • 5.7.1.2 Computer vision
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Cloud computing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Telepathology
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATIONS, BY REGION
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.9.2 INDICATIVE PRICING ANALYSIS, BY OFFERING
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT FROM NEW ENTRANTS
  • 5.10.2 THREAT FROM SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
  • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 END USER ANALYSIS
  • 5.13.1 UNMET NEEDS OF END USERS
  • 5.13.2 END USER EXPECTATIONS
• 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES
  • 5.15.2 CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS
  • 5.15.3 CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 BUSINESS MODELS
• 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY
    • 5.18.2.1 Accelerated biomarker discovery and clinical trial optimization
  • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 Drug discovery & development market
    • 5.18.3.2 Medical imaging & diagnostics market
  • 5.18.4 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biopharmaceutical companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biopharmaceutical companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 TRADE ANALYSIS
  • 5.19.1 IMPORT SCENARIO
  • 5.19.2 EXPORT SCENARIO
• 5.20 US 2025 TARIFF
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON COUNTRY/REGION
    • 5.20.4.1 US
    • 5.20.4.2 Europe
    • 5.20.4.3 Asia Pacific
  • 5.20.5 IMPACT ON END USE INDUSTRIES

6 AI IN PATHOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
• 6.3 NICHE POINT SOLUTIONS
  • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
• 6.4 TECHNOLOGY
  • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET
• 6.5 HARDWARE
  • 6.5.1 HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET
• 6.6 MICROSCOPES
  • 6.6.1 NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH
• 6.7 SCANNERS
  • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
• 6.8 STORAGE SYSTEMS
  • 6.8.1 NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

• 7.1 INTRODUCTION
• 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
  • 7.2.1 FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
• 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
  • 7.3.1 NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
• 7.4 RECURRENT NEURAL NETWORKS (RNNS)
  • 7.4.1 NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET
• 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

• 8.1 INTRODUCTION
• 8.2 IMAGE ANALYSIS
  • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
• 8.3 DIAGNOSTICS
  • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
• 8.4 WORKFLOW MANAGEMENT
  • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
• 8.5 DATA MANAGEMENT
  • 8.5.1 EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND
• 8.6 PREDICTIVE ANALYTICS
  • 8.6.1 GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET
• 8.7 CDSS
  • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
• 8.8 AUTOMATED REPORT GENERATION
  • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
• 8.9 QUALITY ASSURANCE TOOLS
  • 8.9.1 RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH

9 AI IN PATHOLOGY MARKET, BY USE CASE

• 9.1 INTRODUCTION
• 9.2 DRUG DISCOVERY
  • 9.2.1 TARGET IDENTIFICATION & SELECTION
    • 9.2.1.1 Analysis of molecular and histological data for biomarker discovery to fuel market
  • 9.2.2 TARGET VALIDATION
    • 9.2.2.1 Increasing demand for precision medicines to drive market
  • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
    • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
  • 9.2.4 HIT-TO-LEAD IDENTIFICATION
    • 9.2.4.1 Advancements in ML to support market growth
  • 9.2.5 LEAD OPTIMIZATION
    • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
  • 9.2.6 CANDIDATE SELECTION & VALIDATION
    • 9.2.6.1 Critical requirement for regulatory approvals to drive market
• 9.3 DISEASE DIAGNOSIS & PROGNOSIS
  • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
• 9.4 CLINICAL WORKFLOW
  • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
• 9.5 TRAINING & EDUCATION
  • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
• 10.3 HOSPITALS & REFERENCE LABORATORIES
  • 10.3.1 INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND

11 AI IN PATHOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK
  • 11.3.2 UK
    • 11.3.2.1 Increased focus on drug discovery and development to boost demand
  • 11.3.3 GERMANY
    • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
  • 11.3.4 FRANCE
    • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Increased workforce shortage to fuel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Rising cases of infectious and chronic diseases to fuel demand
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on healthcare digitization to boost demand
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strategic investments for AI adoption to support market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growth in pharmaceutical R&D to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing investments for expansion of technological expertise to support growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Offering footprint
    • 12.5.5.3 Use case footprint
    • 12.5.5.4 End user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HOLOGIC, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service launches & approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AKOYA BIOSCIENCES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 INDICA LABS INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 OPTRASCAN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Other developments
  • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 MINDPEAK GMBH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service launches & approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 TRIBUN HEALTH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 TECHCYTE, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service launches & approvals
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Other developments
  • 13.1.12 DEEP BIO INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 LUMEA INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 VISIOPHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product/Service launches & approvals
      • 13.1.14.3.2 Expansions
  • 13.1.15 AETHERAI
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 AIOSYN
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products/Services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product/Service launches & approvals
      • 13.1.16.3.2 Deals
      • 13.1.16.3.3 Other developments
  • 13.1.17 PAIGE AI, INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products/Services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product/Service launches & approvals
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
  • 13.1.18 PROSCIA, INC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products/Services offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product/Service launches & approvals
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 PATHAI, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products/Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product/Service launches & approvals
      • 13.1.19.3.2 Deals
  • 13.1.20 TEMPUS LABS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products/Services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product/Service launches & approvals
• 13.2 OTHER PLAYERS
  • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
  • 13.2.2 DOMORE DIAGNOSTICS AS
  • 13.2.3 QRITIVE
  • 13.2.4 DEEPATHOLOGY LTD
  • 13.2.5 4D PATH INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS